StockData
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Bicara Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$17.47+0.69 (+4.11%)

Close on Oct 19, 2026

Market cap
$1.19B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 9, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026Before market open–––
Q1 FY2026
Ended Mar 31, 2026
May 11, 2026Before market open–$-0.93–
Q4 FY2025
Ended Dec 31, 2025
Mar 30, 2026Before market open–$-0.68–
Q3 FY2025
Ended Sep 30, 2025
Nov 10, 2025Before market open–$-0.67–
Q2 FY2025
Ended Jun 30, 2025
Aug 12, 2025Before market open–––
Q1 FY2025
Ended Mar 31, 2025
May 13, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Mar 27, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open–$-1.60–

Press releases

Announcements Bicara Therapeutics filed with the SEC